著者

半田 智子 柳沢 侑子 南 藍子 竹ノ内 敏孝 坂田 穣 村山 純一郎 原 和夫 前田 正輝 加藤 裕久

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.40, no.1, pp.35-46, 2014-01-10 (Released:2015-01-10)

参考文献数

8

---

The continual development of mobile technology and spread of mobile devices have led to the use of personal digital assistants (PDAs) in medical fields. In this report, we describe the applications of PDAs, such as smartphones, in pharmaceutical practice.Participants included pharmacists in university hospitals (n = 121), community pharmacies (n = 100), and 6th-year pharmacy students (n = 166) who had already successfully completed their clinical rotations. We conducted questionnaires regarding PDA use frequency and interest in future PDA use, which were evaluated using 4-point scales. These two variables were compared statistically between the university hospital pharmacists and community pharmacists. The data from the pharmacy students were analyzed separately using descriptive statistics.For university hospital pharmacists, the top use for PDAs was as a personal scheduler; for community pharmacists, it was as a dispensing error prevention system. Most university hospital pharmacists reported high interest in future PDA use, mainly for obtaining practice guidelines and obtaining package insert information, while community pharmacists would use PDAs to obtain package insert information. For pharmacy students, PDAs were most often used to obtain package insert information; furthermore, pharmacy students showed high interest in future PDA use during hospital and pharmacy clinical rotations.As six interests regarding the use of PDAs in future pharmaceutical practice differed between the university hospital and community pharmacists (P < 0.05), PDA software applications should be tailored for each medical setting.

著者

根来 孝治 若林 仁美 村山 純一郎 中野 泰子

出版者

昭和大学学士会

雑誌

昭和学士会雑誌 (ISSN:2187719X)

巻号頁・発行日

vol.73, no.3, pp.163-170, 2013 (Released:2014-06-23)

参考文献数

31

著者

小林 麻耶 長崎 千尋 坂田 穣 植竹 純子 杉山 創 斉藤 正志 村山 純一郎 佐藤 均 根来 孝治 戸部 敞

出版者

日本医療薬学会

雑誌

日本医療薬学会年会講演要旨集

巻号頁・発行日

vol.14, 2004-09-01

著者

清水 久範 池田 俊也 坂巻 弘之 矢島 秀一 池上 直己 村山 純一郎

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.41, no.3, pp.153-162, 2015-03-10 (Released:2016-03-10)

参考文献数

22

被引用文献数

1 1

---

To evaluate the economic impact of regimens including the oral anticancer drug S-1 (a combination of tegafur, gimeracil, and oteracil), we performed cost-minimization analysis to compare the medical costs of S-1 plus irinotecan (IRIS) with those of conventional intravenous treatment with oxaliplatin or irinotecan plus fluorouracil and folinic acid (mFOLFOX6/FOLFIRI) in patients with advanced colorectal cancer. Patients with advanced colorectal cancer were extracted from the ordering system database for outpatients in Showa University Hospital. Direct medical costs and patients' time-related costs were calculated from the hospital billing data and the average Japanese labor wage, respectively. The results were analyzed from a limited societal perspective. Twenty-nine patients with advanced colorectal cancer were identified, and 25 IRIS regimens, 11 mFOLFOX6 regimens, and 5 FOLFIRI regimens were registered. Mean (± SE) monthly costs of treatment were 183,682 (± 4,767) yen for IRIS regimens and 279,077(± 13,345) yen for mFOLFOX6/FOLFIRI regimens. The monthly cost of IRIS regimens was significantly lower than that of mFOLFOX6/FOLFIRI regimens (P < 0.0001). IRIS regimens are cost-saving compared to mFOLFOX6 or FOLFIRI regimens for the management of advanced colorectal cancer.

著者

岡﨑 敬之介 渡邊 徹 齋藤 勲 村山 純一郎

出版者

公益社団法人 日本薬学会

雑誌

YAKUGAKU ZASSHI (ISSN:00316903)

巻号頁・発行日

vol.132, no.2, pp.231-236, 2012 (Released:2012-02-01)

参考文献数

10

被引用文献数

2 2

---

Our aim was to clarify the side effects of irinotecan which occurred in patients admitted to Showa University Hospital to investigate whether the UGT1A1 genetic polymorphism status was reflected in the discontinuation or dose reduction of irinotecan. We retrospectively investigated UGT1A1 genetic polymorphisms, irinotecan dosage, dose discontinuance or reduction, and laboratory results from May 1 2009 to April 30 2010. The analysis of UGT1A1 genetic polymorphisms in 23 patients showed that frequencies of the UGT1A1*6 and UGT1A1*28 polymorphisms were 35% (eight patients) and 22% (five patients), respectively, and 17% (three patients) were UGT1A1*6/UGT1A1*28 compound heterozygotes. Of all patients who received irinotecan, dose reduction occurred in six patients (38%) and discontinuance in two patients (13%) due to neutropenia and other factors. Of these eight patients, seven (88%) had the UGT1A1*6 and/or *28 polymorphism. The most common irinotecan dose reduction was about 25% of the initial dose. Grade 4 neutropenia was observed in two patients who had the UGT1A1*6 and/or *28 mutation (13%), and one patient was a compound heterozygote. Our investigation confirmed that the UGT1A1 genetic polymorphism status of the patients was reflected in the discontinuance or dose reduction of irinotecan. Our results suggest that Grade 4 neutropenia may occur in patients who are compound heterozygotes and that these patients may need careful selection of treatment regimens possibly involving discontinuance or reduction in irinotecan dosage.

著者

平藤 彰 酒井 麻里 小出 洋子 日山 邦枝 池田 幸 村山 純一郎

出版者

日本歯科薬物療法学会

雑誌

歯科薬物療法 (ISSN:02881012)

巻号頁・発行日

vol.30, no.1, pp.16-19, 2011-04-01 (Released:2011-06-21)

参考文献数

5

---

After implementation of the new GCP, our hospital was staffed by clinical research coordinators (CRC) to smoothly conduct clinical trials of higher quality. At present, two pharmacists, two dental hygienists, and one nurse are working concurrently as CRCs in our hospital. An unique feature of CRC work at our hospital include 1) dental hygienists working as CRCs, and 2) CRCs of different specialities are coordinated on the same trial and contributing according to their specialties, participation of each clinical trial, one by one. Previously, in our hospital, clinical trials for medications had been allocated to nurse CRCs, while dental hygienist CRCs support for clinical trial of medical devices. However, a dental hygienist have participated as a CRC for the first time in a clinical trial for a medication in 2009, a pharmacist CRC cooperated the clinical trial with the dental hygienist CRC, and this trial was successfully completed. We anticipate that dental hygienist CRCs supporting clinical trials in dental practice will play an indispensable role in smoothly conducting clinical trials with high quality. In this report, we will present the current status of CRC work, which has been accomplished by cooperation with pharmacists and dental hygienists.

著者

向後 麻里 斉藤 有深 柏原 由佳 小市 佳代子 市川 幾重 堀地 直也 今井 俊道 足立 満 村山 純一郎 木内 祐二

出版者

公益社団法人日本薬学会

雑誌

藥學雜誌 (ISSN:00316903)

巻号頁・発行日

vol.124, no.12, pp.973-981, 2004-12-01

被引用文献数

1 2

---

日本における肺癌罹患者数は増加傾向にあり, 男性では悪性腫瘍の中で死亡原因の1位となっている. 非小細胞肺癌(non-small-cell lung cancer:NSCLC)は早期診断, 早期切除が原則となってくるが, 進行性肺癌や小細胞肺癌(small-cell lung cancer:SCLC)に対しては外科的切除の適応は少なく, 強力な化学療法や放射線療法が実施されるものの, 5年生存率は1%未満である. 近年, 肺癌の化学療法は, cisplatin(CDDP)と他剤との併用療法が主流でありSCLCではetoposide(VP-16), irinotecan hydrochloride(CPT-11), NSCLCではvinorelbin tartarate(VNR), gemcitabin hydrochloride(GEM)などと併用されている. こうした併用化学療法を安全かつ効率的に実施するためのクリニカル, パス(パス)を用いることは有用と考えられるが, 国内ではいまだ十分には活用されていない. パスとは, 病棟でのチーム医療の「質」と「効率」を同時に保障するために考え出されたマネージメントツールであり, パス導入により, 医療の標準化, チーム医療の推進, 情報の共有などの効果が期待される.